Effects of severe hydronephrosis on surgical outcomes of minimally invasive percutaneous nephrolithotomy (MPCNL).

hydronephrosis minimally invasive operative time percutaneous nephrolithotomy risk factors stone-free rate

Journal

Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques
ISSN: 1895-4588
Titre abrégé: Wideochir Inne Tech Maloinwazyjne
Pays: Poland
ID NLM: 101283175

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 25 04 2023
accepted: 07 05 2023
medline: 8 9 2023
pubmed: 8 9 2023
entrez: 8 9 2023
Statut: ppublish

Résumé

The impact of severe hydronephrosis on the outcomes of minimally invasive percutaneous nephrolithotomy (MPCNL) remains controversial; it is still a subject well worth exploration. To investigate the effects of severe hydronephrosis on surgical outcomes of MPCNL, especially on operative time (OT) and stone-free rate (SFR). In total, 301 patients who underwent MPCNL were included in this study and divided into 4 groups according to the degree of hydronephrosis (nil, mild, moderate, and severe hydronephrosis, respectively). Univariate analyses and multivariate logistic analyses were used to determine the risk factors affecting OT and SFR. Patients with severe hydronephrosis had a longer OT (p < 0.001), a decreased SFR (p < 0.001), and a higher postoperative haemoglobin drop and blood transfusion rate compared to the other 3 cohorts (p = 0.011 and p = 0.043, respectively). Univariate analyses determined that severe hydronephrosis, calyx for access, stone location, stone type, stone size, and number of tracts significantly correlated with OT, while severe hydronephrosis, stone location, stone type, and stone size showed a strong association with SFR (all p < 0.05). Multivariate analyses further identified that severe hydronephrosis (OR = 3.496, p = 0.013), stone location (≥ 4 calyces: OR = 3.024, p = 0.017), stone type (staghorn: OR = 5.204, p = 0.002), and stone size (≥ 1600 mm Severe hydronephrosis is a significant risk factor that can lead to longer OT and lower SFR, and correlates with increased risk of bleeding and blood transfusion rate in some cases during MPCNL. Accordingly, severe hydronephrosis is an influential factor that should not be ignored when performing MPCNL.

Identifiants

pubmed: 37680724
doi: 10.5114/wiitm.2023.128055
pii: 50827
pmc: PMC10481447
doi:

Types de publication

Journal Article

Langues

eng

Pagination

328-342

Informations de copyright

Copyright © 2023 Sekcja Wideochirurgii TChP.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

World J Clin Cases. 2022 Feb 6;10(4):1198-1205
pubmed: 35211553
Arab J Urol. 2015 Dec;13(4):264-9
pubmed: 26609445
Medicine (Baltimore). 2021 Sep 3;100(35):e27014
pubmed: 34477130
Urol Ann. 2016 Jan-Mar;8(1):60-5
pubmed: 26834404
Urolithiasis. 2015 Aug;43(4):355-61
pubmed: 25896255
Med Sci Monit. 2016 Nov 14;22:4363-4368
pubmed: 27842051
Medicina (Kaunas). 2022 Mar 13;58(3):
pubmed: 35334598
Urology. 2011 Jul;78(1):32-6
pubmed: 21296398
Urol Ann. 2017 Jul-Sep;9(3):230-233
pubmed: 28794587
Int Urol Nephrol. 2015 Mar;47(3):441-4
pubmed: 25563232
Turk J Urol. 2020 Nov;46(Supp. 1):S58-S63
pubmed: 32525477
World J Urol. 2020 Oct;38(10):2637-2643
pubmed: 31912223
J Healthc Eng. 2021 Dec 15;2021:5361415
pubmed: 34956571
J Med Assoc Thai. 2006 Jun;89(6):826-33
pubmed: 16850684
Arch Esp Urol. 2019 May;72(4):406-414
pubmed: 31070137
J Endourol. 2004 Oct;18(8):715-22
pubmed: 15659890
Surg J (N Y). 2020 Feb 12;6(1):e19-e23
pubmed: 32055686
Urology. 2015 Apr;85(4):777-81
pubmed: 25704996
J Endourol. 2011 Feb;25(2):327-33
pubmed: 21214412
Urology. 2007 Apr;69(4):603-7
pubmed: 17445632
Urology. 2005 Jul;66(1):38-40
pubmed: 15992882
Eur Urol. 2016 Mar;69(3):475-82
pubmed: 26344917
Urol J. 2020 Jan 26;17(1):8-13
pubmed: 30882169
Sci Rep. 2021 Jul 7;11(1):14050
pubmed: 34234219
J Endourol. 2010 Feb;24(2):201-5
pubmed: 20039821
Urologia. 2022 May;89(2):221-225
pubmed: 33709845
J Endourol. 2011 Aug;25(8):1269-73
pubmed: 21815791
Int J Urol. 2013 Dec;20(12):1193-8
pubmed: 23601020

Auteurs

Wenwei Chen (W)

Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Department of Urology, National Regional Medical Centre, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Zhuxian Shi (Z)

Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Department of Urology, National Regional Medical Centre, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Jie Feng (J)

Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Department of Urology, National Regional Medical Centre, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Changyi Liu (C)

Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Department of Urology, National Regional Medical Centre, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Tao Jiang (T)

Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Department of Urology, National Regional Medical Centre, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Qin Chen (Q)

Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Department of Urology, National Regional Medical Centre, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Yanfeng He (Y)

Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Department of Urology, National Regional Medical Centre, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Hua Zhang (H)

Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Department of Urology, National Regional Medical Centre, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Rui Gao (R)

Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Department of Urology, National Regional Medical Centre, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Houping Mao (H)

Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Department of Urology, National Regional Medical Centre, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Classifications MeSH